More recent studies have instead linked changes in soluble P‐tau (for both CSF and plasma) to the accumulation of Aβ (Sato et al, 2018; Mattsson‐Carlgren et al, 2020a) and shown that changes in soluble P‐tau precede tau aggregation in AD as measured by PET or with neuropathology (Mattsson‐Carlgren et al, 2021). The gene discussed is MAPT; the disease is Alzheimer disease.